Efficacy of Aripiprazole in patients with chronic schizophrenia.

Efficacy of Aripiprazole in patients with chronic schizophrenia. - EArS Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006550

Enrollment

Registered

2011-10-16

Start date

2011-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic schizophrenia

Interventions

We will switch from polypharmacy to Aripiprazole, as a main drug, and follow the treatment for 52 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who is diagnosed as schizophrenia usingDSM-IV-TR. 2)Patients who has been forced to receive massive dose of antipsychotics and polypharmacy for a long term and develop extrapyramidal side effects and other side effets. 3)Patients aged 18 and over. 4)Male ans female patients being managed as inpatients and outpatients. 5)Patients who develop negative symptoms predominantly in comparison with positive symptoms. 6)Patients who meet the criteria for medical economy,and are able to give informed concent.

Exclusion criteria

Exclusion criteria: 1)Patient whose a current psychosis is unstable. 2)Patients who are in coma. 3)Patients who are under strong influence of central-nervous depressants,such as barbiturates /anaesthetics. 4)Patients who have received Vegetamin(r). 5)Patients have received epinephrine. 6)Patients who are under influence of neuroactive action by stimulants,alcohol. 7)Patients who have a history of hypersensitivity reaction to aripiprazole. 8)Female patients who are pregnant or may have become pregnant. 9)Patients who are judged inappropriate by investigator. 10)Patients with intellectual disability concomitantly. 11)Patients with dementia 12)patients with personality disorder concomitantly.

Design outcomes

Primary

Measure	Time frame
Achievement rate of reduction (less or equal two antipsychotics,less or equal 1000mg/day at CP equivalent, and over 20% reduction), Extrapyramidal symptoms (DIEPSS)	—

Secondary

Measure	Time frame
Psychosis (Positive and Negative Syndrome Scale: PANSS), Cognitive function (BACS-J), Preference of medicine (POM)	—

Countries

Japan

Contacts

Public ContactTaku Fukao

Gifu University Department of Psychiatry, Gifu University Graduate School of Medicine

fukataku@gifu-u.ac.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026